A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer (CAELYX)

This study has been terminated.
(Safety reasons)
Sponsor:
Information provided by (Responsible Party):
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
ClinicalTrials.gov Identifier:
NCT02131506
First received: May 5, 2014
Last updated: February 1, 2016
Last verified: February 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: January 2016
  Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)